Amarin Corporation plc

Good morning and welcome to Ameren Corporation's conference call to discuss its second quarter 2026 financial results. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I would now like to turn the conference call over to Devin Sullivan Investor Relations for Ameren.

Thank you for your time and attention this morning as we discuss Ameren's 2026 second quarter financial results. On the call today are Aaron Berg, President and Chief Executive Officer, Steve Ketchum, President R&D and Chief Scientific Officer, and Pete Fishman, Chief Financial Officer. Other members of the senior management team will be available as needed during a Q&A session that will follow these prepared comments. Aaron will provide a state of the company. Steve will provide an update on recent medical and regulatory activities. And Pete will walk us through the numbers. Before we begin, I'd like to remind everyone that today's press release and related quarterly report on Form 10Q will be available on the investor relations section of the company's website. www.amroncorp.com as will a replay of this call shortly after its completion. Please be aware that during this call we may make certain statements related to our business that are deemed forward-looking statements under federal securities laws. These statements are not guarantees of future performance but rather are subject to a variety of risks and uncertainties. Our actual results could differ materially from expectations reflected in any forward-looking statements. Additionally, we assume no obligation to update these statements as circumstances change. For a discussion of the material risks and important factors that could affect our actual results, please refer to our SEC filings, which are available either on our company website or the Securities and Exchange Commission's EDGAR system. With that said, I'd now like to turn the call over to Ameren's President and CEO Aaron Berg Aaron, please go ahead.

Thanks, Devin, and thank you all for joining us today. Q2 2026 marked an inflection point for Ameren, highlighting the one year anniversary of our dual commercial strategy that combines continued execution of our U.S. business with a fully partnered international commercial platform. The successful implementation of these actions has resulted in a scalable business model while defining a clear path towards sustainable growth and profitability. We're seeing a promising early stage international sales trajectory in a number of markets where there remains significant unmet need and long-term potential for VSCEPA while preserving a leading US presence for VSCEPA supported by a financial foundation that includes a growing cash position and no debt. Our restructuring activities are now complete, resulting in a significantly lower cost base. This refined organizational structure and expense framework will enhance our ability to efficiently execute our long term growth strategy. As you may have noticed in our press release, were now able to provide an outlook for certain key metrics for full year 2026, reflecting the clarity afforded by our new operating model and the strong partnerships that make up its foundation. This underscores how far the business has progressed in the past year while validating our global go-to-market initiatives and reinforcing the continued outstanding execution of our talented, committed team. As of June 30th, 2026, the SEPA was commercially available in 22 countries via both our fully partnered international commercial strategy and company managed US presence. Our accelerating international growth is being driven primarily by our exclusive license and supply agreement with Record Audi, which covers 59 countries across Europe, as well as our six other commercial partnerships in the rest of the world. that cover regions including Canada, China, Israel, the Middle East, Asia, Australia, and New Zealand. Across this combined global partner network, in-market demand for Vesipa rose by 59% in cumulative year-over-year volume as of June 30th compared to the same period last year. As of the end of Q2, Beskepa is commercialized in 11 countries in Europe, including a recent launch in Romania, and Recordati continues to invest meaningfully with pricing, reimbursement, market access, and adoption, advancing in numerous additional countries across the licensed territory. Under Recordati's leadership, Beskepa is in an early but promising stage of commercialization in Europe's large cardiovascular market, where the disease affects an estimated 62 million people and carries an annual economic burden of approximately 282 billion euro across the European Union. In-market demand in Europe from Escefa under the Recordati partnership rose by 69% in Q2 2026 from Q2 2025. Spain and the UK, though early, are leading commercial adoption providing a strong foundation for future growth as pricing, reimbursement, and commercialization efforts continue across the broader territory. In Italy, where Recordati is one of the country's most established pharmaceutical commercial organizations, Vescappa launched with significant commercial support and has demonstrated strong early uptake. Vaskepa is positioned by Recordati as a priority brand in its cardiovascular portfolio, backed by an expanded cardiovascular commercial infrastructure across Europe, including dedicated field representatives, medical science liaisons, and marketing investment. In its 2025 annual report, Recordati referred to Vaskepa as a best-in-class treatment option that complements its existing cardiovascular portfolio is supported by a robust clinical data package and makes a meaningful impact for cardiovascular patients with residual cardiovascular risk. While driving utilization in launch markets, Recordati is actively progressing pricing, reimbursement, and market access across additional territories, building a meaningful base for long-term royalty and milestone growth as additional countries come online. While very early, the commercial performance since the June 2025 licensing transaction is encouraging in that Recordati's established cardiovascular infrastructure, broader geographic footprint, and tremendous execution have unlocked substantially greater value from Vescapa than would have otherwise been possible had Ameren continued Vescapa commercialization throughout Europe alone. The commercial momentum generated by Recordati thus far materially exceeds historical European growth rates achieved by Ameren prior to the licensing transaction. As a reminder, European markets each follow their own regulatory process for pricing, reimbursement, and market access, so commercial launches can progress at different speeds and under varying requirements across countries despite an overarching EU framework. In the U.S., our core business continues to serve as a highly efficient cash generating base with FACIPA retaining a leading position in the eicosapent ethyl market despite ongoing generic pressure. We continue to expect to maintain our exclusives with key payers through the end of 2026. The overall US IPE market, based on third party data, rose by 3% in Q2 2026 compared to Q2 2025. The SEPA share of the market rose to 48% as of June 30th, 2026, up from 43% in the same period last year. Despite continued pricing pressure, the SEPA branded prescriptions increased 14% year over year in the second quarter of 2026, reflecting continued commercial execution in the competitive market. We expect US volumes to remain stable through the end of 2026. Outside of Europe and the US, we continue to support our partners in advancing regulatory submissions in various other countries across Asia. We recently received approvals in Singapore and South Korea and look forward to the launches in these territories in 2027. As our international footprint continues to expand, the work of our medical affairs, regulatory, and R&D teams becomes increasingly important. Beyond supporting IMRN's own scientific objectives, these teams provide critical expertise to our commercialization partners around the world to contribute to our joint success, helping them navigate local regulatory requirements continuing to contribute to an already robust library of scientific evidence supporting the benefits and unique attributes of icosapen ethyl, engage with key scientific leaders, support reimbursement discussions, and prepare for successful product launches. Through scientific exchange, Congress participation, publication support, medical education initiatives, and ongoing regulatory collaboration, These teams help ensure that our partners have access to the latest data and insights supporting the SEPA as they work to improve access for patients in their respective markets. To provide additional perspective on the scientific, medical, and regulatory activities supporting our global growth strategy, I'll now turn the call over to Steve Ketchum.